Form 8-K - Current report:
SEC Accession No. 0001104659-24-109521
Filing Date
2024-10-17
Accepted
2024-10-17 16:01:29
Documents
14
Period of Report
2024-10-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2426349d1_8k.htm   iXBRL 8-K 30825
2 EXHIBIT 10.1 tm2426349d1_ex10-1.htm EX-10.1 70032
  Complete submission text file 0001104659-24-109521.txt   288613

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elox-20241016.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elox-20241016_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elox-20241016_pre.xml EX-101.PRE 22365
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2426349d1_8k_htm.xml XML 3452
Mailing Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472 781-577-5300
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

EIN.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 241377578
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)